(Circulation. 1998;98:2805-2814.)
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports* |
TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction
Results of the TIMI 10B Trial
From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (C.P.C., C.H.M., R.P.G., E.B.); West Roxbury (Mass) Veterans Administration Medical Center (C.M.G.); Royal Victoria Hospital, Belfast, Northern Ireland, UK (A.A.J.A.); Baystate Medical Center, Springfield, Mass (M.J.S.); University of Miami/Jackson Memorial Hospital, Miami, Fla (R.F.S.); CHU Côte de Nacre, Caen, France (G.G.); Sarasota Memorial Hospital, Sarasota, Fla (M.F.); Montefiore Medical Center, Bronx, NY (H.S.M.); Winthrop University Hospital, Mineola, NY (R.M.S.); Henry Ford Heart and Vascular Institute, Detroit, Mich (W.D.W.); and University Hospitals Leuven, Leuven, Belgium (F.V.d.W.).
Background—Bolus thrombolytic therapy is a simplified means of administering thrombolysis that facilitates rapid time to treatment. TNK-tissue plasminogen activator (TNK-tPA) is a highly fibrin-specific single-bolus thrombolytic agent.
Methods and Results—In TIMI 10B, 886 patients with acute ST-elevation myocardial infarction presenting within 12 hours were randomized to receive either a single bolus of 30 or 50 mg TNK-tPA or front-loaded tPA and underwent immediate coronary angiography. The 50-mg dose was discontinued early because of increased intracranial hemorrhage and was replaced by a 40-mg dose, and heparin doses were decreased. TNK-tPA 40 mg and tPA produced similar rates of TIMI grade 3 flow at 90 minutes (62.8% versus 62.7%, respectively, P=NS); the rate for the 30-mg dose was significantly lower (54.3%, P=0.035) and was 65.8% for the 50-mg dose (P=NS). A prespecified analysis of weight-based TNK-tPA dosing using median TIMI frame count demonstrated a dose response (P=0.001). Similar dose responses were observed for serious bleeding and intracranial hemorrhage, but significantly lower rates were observed for both TNK-tPA and tPA after the heparin doses were lowered and titration of the heparin was started at 6 hours.
Conclusions—TNK-tPA, given as a single 40-mg bolus, achieved rates of TIMI grade 3 flow similar to those of the 90-minute bolus and infusion of tPA. Weight-adjusting TNK-tPA appears to be important in achieving optimal reperfusion; reduced heparin dosing appears to improve safety for both agents. Together with the safety results from the parallel Assessment of the Safety of a New Thrombolytic: TNK-tPA (ASSENT I) trial, an appropriate dose of this single-bolus thrombolytic agent has been identified for phase III testing.
Key Words: thrombolysis • myocardial infarction • plasminogen activators
This article has been cited by other articles:
 |
|
 |
|
  S. Schulman, R. J. Beyth, C. Kearon, and M. N. Levine Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 257S - 298S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J B Jones and A Docherty Non-invasive treatment of ST elevation myocardial infarction Postgrad. Med. J., December 1, 2007; 83(986): 725 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Boden, K. Eagle, and C. B. Granger Reperfusion Strategies in Acute ST-Segment Elevation Myocardial Infarction: A Comprehensive Review of Contemporary Management Options J. Am. Coll. Cardiol., September 4, 2007; 50(10): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Alexander, L. K. Newby, P. W. Armstrong, C. P. Cannon, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2570 - 2589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]
|
|
|
|
 |
|
 D K Pedley and W G Morrison Role of thrombolytic agents in cardiac arrest. Emerg. Med. J., October 1, 2006; 23(10): 747 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zaitsev, K. Danielyan, J.-C. Murciano, K. Ganguly, T. Krasik, R. P. Taylor, S. Pincus, S. Jones, D. B. Cines, and V. R. Muzykantov Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Blood, September 15, 2006; 108(6): 1895 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Gershlick, A. Stephens-Lloyd, S. Hughes, K. R. Abrams, S. E. Stevens, N. G. Uren, A. de Belder, J. Davis, M. Pitt, A. Banning, et al. Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction N. Engl. J. Med., December 29, 2005; 353(26): 2758 - 2768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Le May, G. A. Wells, M. Labinaz, R. F. Davies, M. Turek, D. Leddy, J. Maloney, T. McKibbin, B. Quinn, R. S. Beanlands, et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study) J. Am. Coll. Cardiol., August 2, 2005; 46(3): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chua, C. Lo, E.-M. Babor, M. S. Sabatine, C. P. Cannon, E. Braunwald, and the CLARITY-TIMI 28 Investigators Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction N. Engl. J. Med., June 23, 2005; 352(25): 2647 - 2648. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, D. A. Morrow, R. P. Giugliano, P. B.J. Burton, S. A. Murphy, C. H. McCabe, C. M. Gibson, and E. Braunwald Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes Circulation, April 26, 2005; 111(16): 2042 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Haley Jr, P. D. Lyden, K. C. Johnston, T. M. Hemmen, and the TNK in Stroke Investigators A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke Stroke, March 1, 2005; 36(3): 607 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, S. A. Murphy, A. J. Kirtane, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and TIMI Study Group Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction J. Am. Coll. Cardiol., September 1, 2004; 44(5): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, J. Karha, S. A. Murphy, J. A. de Lemos, D. A. Morrow, R. P. Giugliano, M. T. Roe, R. A. Harrington, C. P. Cannon, E. M. Antman, et al. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1170 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A Rowley, S Vijayasekaran, P K Yu, I L McAllister, and D-Y. Yu Retinal toxicity of intravitreal tenecteplase in the rabbit Br. J. Ophthalmol., April 1, 2004; 88(4): 573 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, D. S. Pinto, S. A. Murphy, D. A. Morrow, H.-P. Hobbach, S. D. Wiviott, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1535 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T K Nordt and C Bode Thrombolysis: newer thrombolytic agents and their role in clinical medicine Heart, November 1, 2003; 89(11): 1358 - 1362. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Dubois, A. Belmans, C. B. Granger, P. W. Armstrong, L. Wallentin, P. M. Fioretti, J. L. Lopez-Sendon, F. W. Verheugt, J. Meyer, F. Van de Werf, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, J. Karha, S. A. Murphy, D. James, D. A. Morrow, C. P. Cannon, R. P. Giugliano, E. M. Antman, E. Braunwald, and TIMI Study Group Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials J. Am. Coll. Cardiol., July 2, 2003; 42(1): 7 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano, M. T. Roe, R. A. Harrington, C. M. Gibson, U. Zeymer, F. Van de Werf, K. W. Baran, H.-P. Hobbach, L. H. Woodlief, K. L. Hannan, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic urial J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1251 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Stewart, M. Kong, V. Novokhatny, G. Jesmok, and V. J. Marder Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage Blood, April 15, 2003; 101(8): 3002 - 3007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Baker Jr Thrombolytic Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 291 - 314. [PDF]
|
|
|
|
 |
|
 H. P. Selker, J. R. Beshansky, J. L. Griffith, and for the TPI Trial Investigators* Use of the Electrocardiograph-Based Thrombolytic Predictive Instrument To Assist Thrombolytic and Reperfusion Therapy for Acute Myocardial Infarction: A Multicenter, Randomized, Controlled, Clinical Effectiveness Trial Ann Intern Med, July 16, 2002; 137(2): 87 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Llevadot, R. P. Giugliano, and E. M. Antman Bolus Fibrinolytic Therapy in Acute Myocardial Infarction JAMA, July 25, 2001; 286(4): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 1 Circulation, June 12, 2001; 103(23): 2862 - 2866. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, J. A. de Lemos, S. A. Murphy, S. J. Marble, C. H. McCabe, C. P. Cannon, E. M. Antman, and E. Braunwald Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction : A TIMI 14 Substudy Circulation, May 29, 2001; 103(21): 2550 - 2554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Chapman, P. Lyden, P. A. Lapchak, S. Nunez, H. Thibodeaux, and J. Zivin Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model Stroke, March 1, 2001; 32(3): 748 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Armstrong, C. Granger, and F. Van de Werf Bolus Fibrinolysis : Risk, Benefit, and Opportunities Circulation, February 27, 2001; 103(8): 1171 - 1173. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom, S. R. Mehta, J. Pogue, and S. Yusuf Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials: Intracranial Hemorrhage in Trials of Bolus Thrombolytic Therapy JAMA, January 24, 2001; 285(4): 444 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy Intravenous Thrombolysis in Acute Myocardial Infarction Chest, January 1, 2001; 119(1_suppl): 253S - 277S. [Full Text] [PDF]
|
|
|
|
|
|
H. V. Barron, C. P. Cannon, S. A. Murphy, E. Braunwald, and C. M. Gibson Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction : A Thrombolysis In Myocardial Infarction 10 Substudy Circulation, November 7, 2000; 102(19): 2329 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Stewart, J. C. Fredenburgh, B. A. Leslie, B. A. Keyt, J. A. Rischke, and J. I. Weitz Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator J. Biol. Chem., March 31, 2000; 275(14): 10112 - 10120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.B.A Menown, G Mackenzie, and A.A.J Adgey Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infarction Eur. Heart J., February 2, 2000; 21(4): 275 - 283. [Abstract] [PDF]
|
|
|
|
|
|
C. M. Gibson, C. P. Cannon, S. A. Murphy, K. A. Ryan, R. Mesley, S. J. Marble, C. H. McCabe, F. Van de Werf, and E. Braunwald Relationship of TIMI Myocardial Perfusion Grade to Mortality After Administration of Thrombolytic Drugs Circulation, January 18, 2000; 101(2): 125 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1395 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, S. Murphy, I. B. A. Menown, R. F. Sequeira, R. Greene, F. Van de Werf, M. J. Schweiger, M. Ghali, M. J. Frey, K. A. Ryan, et al. Determinants of coronary blood flow after thrombolytic administration J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1403 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.J. Van de Werf The ideal fibrinolytic: can drug design improve clinical results? Eur. Heart J., October 2, 1999; 20(20): 1452 - 1458. [PDF]
|
|
|
|
|
|
M. J. Tanasijevic, C. P. Cannon, E. M. Antman, D. R. Wybenga, G. A. Fischer, C. Grudzien, C. M. Gibson, J. W. Winkelman, E. Braunwald, and for the TIMI 10B Investigators Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: Results from the thrombolysis in myocardial infarction study (TIMI) 10B J. Am. Coll. Cardiol., September 1, 1999; 34(3): 739 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Ryan, E. M. Antman, N. H. Brooks, R. M. Califf, L. D. Hillis, L. F. Hiratzka, E. Rapaport, B. Riegel, R. O. Russell, E. E. Smith III, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J. Am. Coll. Cardiol., September 1, 1999; 34(3): 890 - 911. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson Primary Angioplasty Compared with Thrombolysis: New Issues in the Era of Glycoprotein IIb/IIIa Inhibition and Intracoronary Stenting Ann Intern Med, May 18, 1999; 130(10): 841 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, S. A. Murphy, M. J. Rizzo, K. A. Ryan, S. J. Marble, C. H. McCabe, C. P. Cannon, F. Van de Werf, and E. Braunwald Relationship Between TIMI Frame Count and Clinical Outcomes After Thrombolytic Administration Circulation, April 20, 1999; 99(15): 1945 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, C. P. Cannon, S. A. Murphy, S. J. Marble, H. V. Barron, E. Braunwald, and for the TIMI Study Group Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction Circulation, April 23, 2002; 105(16): 1909 - 1913. [Abstract] [Full Text] [PDF]
|
|